Tepotinib (Tepmetko)

Targeted TherapyApproved for: NSCLCBiomarker: MET Exon 14 Skipping Tepotinib (Tepmetko) is a FDA-approved treatment for adults with metastatic non-small cell lung cancer (NSCLC) who are harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Related Research News U.S. FDA Approves Mirati’s...
|
May 27, 2021
|